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Abstract
Background: Pterygium is a common ocular surface disease characterized by abnormal epithelial and fibrovascular
proliferation, invasion, and matrix remodeling. This lesion, which migrates from the periphery to the center of the cornea,
impairs vision and causes considerable irritation. The mechanism of pterygium formation remains ambiguous, and current
treatment is solely surgical excision, with a significant risk of recurrence after surgery. Here, we investigate the role of
methylation in DNA sequences that regulate matrix remodeling and cell adhesion in pterygium formation.
Methodology/Principal Findings: Pterygium and uninvolved conjunctiva samples were obtained from the same eye of
patients undergoing surgery. The EpiTYPER Sequenom technology, based on differential base cleavage and bisulfite
sequencing was used to evaluate the extent of methylation of 29 matrix and adhesion related genes. In pterygium, three
CpG sites at 2268, 232 and 229 bp upstream of transglutaminase 2 (TGM-2) transcription initiation were significantly
hypermethylated (p,0.05), whereas hypomethylation was detected at CpGs +484 and +602 bp downstream of matrix
metalloproteinase 2 (MMP-2) transcription start site, and 2809, 2762, 2631 and 2629 bp upstream of the CD24
transcription start site. RT-qPCR, western blot and immunofluorescent staining showed that transcript and protein
expression were reduced for TGM-2 and increased for MMP-2 and CD24. Inhibition of methylation in cultured conjunctival
epithelial cells increased these transcripts.
Conclusions/Significance: We found regions of aberrant DNA methylation which were consistent with alteration of TGM-2,
MMP-2, and CD24 transcript and protein expression, and that inhibition of methylation in cultured cells can increase the
expression of these genes. Since these genes were related to cell adhesion and matrix remodeling, dysregulation may lead
to fibroblastic and neovascular changes and pterygium formation. These results have implications for the prognostication of
pterygium in clinical practice, for example, detection of epigenetic changes may have a role in predicting post surgical
recurrence of aggressive lesions.
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Introduction
Pterygium is a common fibrovascular ocular surface disease
characterized by migration of wedge-shaped abnormal tissue from
bulbar conjunctiva onto the cornea. Morbidity incurred by
pterygium includes irritation, redness, and visual impairment in
instances, such as visual occlusion induced by a large pterygium
that has migrated to the visual axis over the central cornea, and
irregular astigmatism or impaired tear film regularity induced by
pterygium. The pathogenesis of this disease, however, remains
ambiguous. Compelling evidence that UV-mediated limbal
damage triggers this pathogenesis has been reviewed [1]. Other
causes proposed include aberrant wound healing mechanisms [2–
4], genetic instability [5], stem cell dysfunction [6], metabolic
disorder [7], and neuronal dysfunction [8].
Epigenetic modifications of gene expression are known to play
an established role in the development of human cancers [9]. Both
DNA hypo- and hypermethylation within promoter-rich cytosine
guanine dinucleotide (CpG) islands have given rise to cancers
[10,11]. Additionally, DNA methylation has long been suspected
to mediate some of the effects of aging, environmental exposures
and lifestyle factors on risk of non-neoplastic diseases [12,13].
Epigenetic changes have been implicated in the control of wound
healing [14,15]. For example, wound healing and fibrosis in the
liver is mediated by critical processes controlled by DNA
methylation [14]. DNA methylation in mammals occurs predom-
inantly at the CpG islands, and approximately 60–90% of the
dinucleotides are modified [16]. This DNA modification in gene
promoters causes transcriptional repression by directly interfering
with the binding of transcription factors to DNA, or alternatively,
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proteins that block access to the factors responsible for induction of
the gene [16]. Within the field of epigenetics, DNA methylation
patterns are fast becoming an increasing interest to the scientific
community. Changes in DNA methylation are a dynamic process
and the resulting patterns are tightly associated to disease. In the
case of the ocular surface, such changes are more likely to be
spatially confined to one part of the tissue to cause disease,
compared to changes in genomic sequences, which are ubiquitous
and tend to be present in both the diseased and normal tissue.
Promoter methylation has been known to play important roles
in genes related to wound healing. For example, transglutaminase
2 (TGM-2) is involved in corneal wound healing [17], and is
regulated epigenetically by promoter methylation [18]. TGM-2, a
family member of transglutaminases, is a ubiquitously expressed
protein comprised of a single ,76 kDa polypeptide. It exhibits
calcium-dependent protein cross-linking activity [19], and en-
hances cell adhesion and intracellular signaling, and extracellular
matrix (ECM) remodeling [20].
Wound healing processes are also mediated by the matrix
metalloproteinases (MMP) such as MMP-2, which is primarily
secreted by keratocytes in the cornea and mediates long-term
stromal remodeling and basement membrane synthesis [21]. This
protein has been shown to be increased during corneal repair
[21,22], and is known to be regulated by DNA methylation [23].
Recently, a cell adhesion molecule that has never been
previously associated with pterygium, CD24, was reported to be
upregulated and localized in the nuclei in pterygium epithelium
which suggest that cell adhesion properties may be disrupted [24].
CD24, also known as heat-stable antigen in the mouse, is a
glycoprotein of heterogeneous molecular weight ranging from 30
to 70 kDa [25]. CD24 has been repeatedly detected in gene
expression profiling to identify genes which expression correlates
with tumorigenesis and tumor progression [26–28]. Moreover,
CD24 has been demonstrated to promote tumor cell invasiveness
in animal model [29] and in vitro [30].
Despite the important findings on promoter methylation and
wound healing, there has been no reported study on the aberrant
methylation in pterygium. We have previously investigated the
genes specifically involved in wound healing mechanisms such as
TGM-2, MMP-2, and CD24 in pterygium [24]. Here, we report
for the first time the role of methylation in the pathogenesis of
pterygium, by profiling the methylation status of TGM-2, MMP-2,
and CD24 gene promoters and the effect of methylation in
cultured ocular surface cells.
Results
DNA methylation analysis
The methylation status at the promoters of TGM-2, MMP-2,
and CD24 genes was significantly different between pterygium and
uninvolved conjunctiva samples in at least one CpG unit. Since
DNA methylation is generally a form of negative regulation of
gene transcription [31], a relatively higher level of methylation at a
particular CpG island was considered to be biologically important
if this corresponded to a relatively lower expression of the
transcript in this tissue, and vice versa. Using this approach, out of
29 tested genes, the methylation status of the CpG units of the
following 3 genes was considered to be biologically important:
CpG 1 and 17/18 at the TGM-2 promoter; CpG 14/15 at the
CD24 promoter (CD24_01); CpG 5 and 24/25 at the CD24
promoter (CD24_02); and CpG 12 and 18 at the MMP-2
promoter. The numbers of the CpG refers to the numbered CpG
units along the EpiTYPER target sequences. The relative
methylation level of pterygium and conjunctival sample in each
patient, as well as the mean methylation are tabulated in Table 1.
Figure 1 shows the epigrams highlighting the CpGs that were
methylated to a significantly different extent between pterygium
and uninvolved conjunctiva.
Supplementary Figure S1 shows three specific CpG islands
that were significantly hypermethylated in pterygium in compar-
ison to conjunctiva tissue, located at the 2268, 232 and 229
positions of TGM-2 transcription start site (NCBI accession
no. U13920). These positions corresponded to 2367, 2131 and
2128 bp, respectively, upstream of the translation start site.
Figure S2 illustrates a differentially hypomethylated CpG unit in
pterygium tissue, which was located at the +484 and +602 bp
downstream of MMP-2 transcription start site (NCBI accession no.
NM_004530.4). In Figure S3A, a CpG unit located 2698 bp
upstream of CD24 transcription start site (NCBI accession
no. Y14692), corresponding to 2809 bp upstream of the start
codon, was shown to be significantly hypomethylated in the
pterygium tissue. Other differentially hypomethylated CpG units
were located 2762, 2631 and 2629 bp upstream of the CD24
transcription start site (Figure S3B).
Effect of 5-aza-29-deoxycytidine treatment
In order to determine whether DNA methylation might be a
general phenomenon that controls cell-specific TGM-2, MMP-2,
and CD24 expression in the conjunctiva, we treated spontaneously
immortalized human conjunctival epithelial cells (IOBA-NHC)
with 5-aza-29-deoxycytidine (5-aza-dC) and monitored TGM-2,
MMP-2, and CD24 mRNA expression. The methyltransferase
inhibitor, 5-aza-dC, stimulated the upregulation of TGM-2,
MMP-2, and CD24 (Figure 2) and demonstrated a dose-
dependent effect on the mRNA levels of the three transcripts,
with a maximal level of mRNA expressed at an inhibitor
concentration of 3 mM.
TGM-2, MMP-2, and CD24 expression
TGM-2, MMP-2, and CD24 gene transcripts were detected in
conjunctiva and pterygium tissues. TGM-2 transcript was
downregulated by 0.4260.03 fold (p,0.05) in pterygium relative
to the conjunctiva. MMP-2 and CD24 transcripts however, were
upregulated 2.4460.52 fold and 2.0360.22 fold (p,0.05),
respectively in pterygium compared to normal conjunctiva. A
bar graph summarizing the fold differences of these genes in
pterygium tissue compared to the conjunctiva tissue is illustrated in
Figure 3A.
Immunofluorescent staining detected the presence of TGM-2,
MMP-2, and CD24 in human conjunctiva and pterygium tissue
(Figure 3B). No fluorescent signals were detected in negative
controls (data not shown). TGM-2 was expressed superficially in
the conjunctival epithelium. Strong staining was observed in the
basement membrane of the conjunctiva, which was obviously
absent in the pterygium.
MMP-2 and CD24 protein expression was attenuated in the
normal conjunctiva. MMP-2 was distributed mainly in the basal
and a few layers of suprabasal cells in the pterygium epithelium.
Some fibroblasts adjacent to the epithelial layer were also stained
with the MMP-2 (Figure 3B). CD24 was expressed in almost all
layers of the pterygium epithelium. Nuclear staining was mainly
present in the basal and some suprabasal cells. A few cells were
found to be expressed in the plasma membrane (Figure 3B).
Western blot further confirmed the expression levels observed in
the immunostaining and the mRNA levels detected by the RT-
PCR (Figure 3C). TGM-2 protein level was relatively lower in
the pterygium compared to the conjunctival tissue. In contrast,
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CpG Patient Methylation level Mean methylation±SD Transcription
Sample position* no. P C P C p-value level***
TGM-2 CpG 1 1 0.11 0.12 0.26060.131 0.10060.085 0.015 TGM-2 was
2 0.49 0.05 downregulated
3 0.31 0.25 0.479 fold
4 0.20 0.07 in pterygium
5 0.26 0 relative to
6 0.19 0.11 conjunctiva
CpG 17/18 1 0.13 0.04 0.25660.144 0.06060.041 0.005
2 0.46 0.06
3 0.42 0.13
4 0.16 0.01
5 0.20 0.08
6 0.17 0.04
MMP-2 CpG 12 1 0.01 0.17 0.04260.038 0.16260.022 2.85610
25 MMP-2 was
2 0.01 0.13 upregulated
3 0.09 0.17 1.324 fold
4 0.09 0.17 in pterygium
5 0.02 0.14 relative to
6 0.03 0.19 conjunctiva
CpG 18 1 0.01 0.07 0.01760.018 0.05760.030 0.009
2 0.04 0.10
3 0 0.01
4 0.04 0.06
5 0 0.04
6 0.01 0.06
CD24_01** CpG 14/15 1 0.17 0.29 0.12060.123 0.33760.122 0.006 CD24 was
2 0.10 0.12 upregulated
3 0.33 0.43 3.42 fold in
4 0 0.45 pterygium
5 0 0.40 relative to
6 0.12 0.33 conjunctiva
CD24_02** CpG 5 1 0.14 0.15 0.07860.077 0.24360.097 0.004
2 0.02 0.23
3 0.18 0.35
4 0 0.22
5 0.01 0.14
6 0.12 0.37
CpG 24/25 1 0.20 0.28 0.14260.142 0.37260.154 0.011
2 0.04 0.13
3 0.35 0.51
4 0.01 0.33
5 0.01 0.45
6 0.24 0.53
P refers to pterygium and C refers to conjunctiva.
*The position of the CpG refers to the numbered CpG units along the EpiTYPER target sequences.
**More than one sequences were used for this promoter and found to be differentially methylated.
***Transcription levels were based on our previously published work (see reference #24).
doi:10.1371/journal.pone.0014687.t001
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pterygium compared to the conjunctiva tissue.
In situ zymography showed that pterygium had relatively higher
gelatinolyticactivityinthe epithelium thanconjunctiva(Figure 3D).
No fluorescent signals were detected in sections treated with
metalloproteinase inhibitor, 1,10-phenanthroline (data not shown).
Discussion
In this study, we demonstrate a significant increase in both
MMP-2 and CD24 transcript and protein levels in pterygium
tissue, with less methylation in the corresponding genomic
sequences. In contrast, TGM-2 mRNA and protein levels were
reduced in the pterygium tissue.
Previous studies in pterygium have shown MMPs to play a role
in the pathogenesis of pterygium [1,32,33]. Elevated MMP-2
detected in pterygium has been shown to facilitate the invasive
property of pterygium by degrading components of their basement
membrane and adjacent stromal matrix [32]. In addition,
increased MMP-2 activity in skin fibroblasts has been considered
as the key mediator between the increased protease activity and
reduced cell adhesion [34].
TGM-2 has been known to cross-link fibronectin, collagen type I,
fibrin, and many other ECM proteins after its release from cells
exposed to stress or trauma [35]. ECM- bound TGM-2 has been
proposed to provide a shield around wounds thereby protecting the
structural integrity of the wounded cellsfrom further damage [36]. In
addition, a decrease in TGM-2 activity has been reported to result in
concomitant attenuation in cell adhesion [37], which may for
example, facilitate migration of abnormal pterygium tissue towards
the central cornea. Many other known functions of TGM-2 in wound
healing that may explain pterygium formation have been reported,
including effects on myofibroblasts [38]. Pterygium has been linked to
abnormal cell transformation such as epithelial-mesenchymal
transition (EMT) to a myofibroblastic phenotype [39]. During
EMT,epithelialcellsshowlessintercellularadherencejunctions,tight
junctions, and desmosomes leading to the loss of cellular polarity.
Cytokeratinintermediatefilamentsarealsodisassembled torearrange
their F-actin stress fibers to express filopodia and lamellipodia [40].
Transmission electron micrograph showed that basal pterygium
epithelial cells had higher cytoplasmic electron density with
cytoplasmic fibrils, and the epithelial cells that invaded the underlying
stroma no longer showed adhesion complexes and had enlarged
intercellular spaces [41]. In addition, co-expression of cytokeratins
with a-SMA indicates a classic sign of EMT and the role of
myofibroblasts in the progression of pterygium [41].
Numerous studies have linked CD24 with tumorigenesis and
tumor progression [26,28]. CD24 is able to promote tumor cell
proliferation and alter the adhesive properties of tumor cells to P-
selectin, fibronectin, collagens type I and IV, and laminin [30].
Additionally, cell spreading, motility, and invasiveness are also
strongly increased upon CD24 expression [30]. In pterygium, the
elevated CD24 expression may cause increased proliferation, motility
and invasiveness of pterygium epithelial cells and fibroblasts.
Our study has indicated that the changes in TGM-2, MMP-2,
and CD24 expression in the human conjunctival epithelial cells
can be regulated by DNA methylation. Concomitantly, previous
studies have highlighted the importance of TGM-2 and MMP-2
promoter methylation for the expression of these genes [18,23,42],
but there has been no previous report concerning the epigenetic
regulation of the human CD24.
Demethylation of the TGM-2 promoter at two HpaII tiny
fragment (HTF) islands: HTF-1 (+1t o2215 with reference to
start of transcription) and HTF-2 (21315 to 21415), has been
linked to tumor cell phenotype [42]. In contrast, we found that the
3 CpG units that were relatively hypermethylated were located at
the 2268, 232 and 229 bp from the beginning of the transcript,
suggesting that hypermethylation upstream of the transcription
start site may interfere with binding of some transcription factors,
thereby reducing TGM-2 transcription.
Differential methylation of the MMP-2 promoter has been
reported in the region up to +733 bp from the transcription start
site, in a breast cancer cell line [23]. In this study, we found a
hypomethylated CpG unit located +484 and +602 bp downstream
of MMP-2 transcription start site in pterygium.
TGM-2, MMP-2 and CD24 are shown to be linked to one
another and other important intracellular signaling molecules
either indirectly, or directly, in known biological pathways
(Figure 4). The molecules in the pathways and the Medline
references (PMID numbers) corresponding to the illustrated
relationships are tabulated in the supplementary data (Table S1
and S2). The observed biological effects of the gene expression
changes may be more than expected based on differential
methylation of individual genes. For example, TGM-2 can
activate MMP-2 in skin fibroblasts [43], increasing the overall
biological effect of the pathways mediated by TGM-2 and MMP-
2. Another example would be the upregulation of CD24 in
microglial cells [44] and MMP-2 in head and neck squamous cell
carcinoma [45] by granulocyte-macrophage colony stimulating
factor (CSF2). This raises the possibility that critical DNA
demethylation may facilitate transcription factor(s) downstream
of CSF2 to bind to regulatory sequences of CD24 and MMP-2,
with a consequential increase in Wnt/b-catenin signaling, which
has been previously reported in pterygium [41]. The canonical
Figure 2. The effect of 5-aza-29-deoxycytidine (5-aza-dC) on
transglutaminase 2 (TGM-2), matrix metalloproteinase 2
(MMP-2) and CD24 transcript levels in human conjunctival
epithelial cells. Cultured conjunctival epithelial cells (IOBA-NHC) were
treated with 1, 2 or 3 mM of 5-aza-dC.
doi:10.1371/journal.pone.0014687.g002
Figure 1. Epigrams showing the nucleotide sequences used in the EpiTYPER Sequenom study. It was obtained from genes known to be
important for matrix remodeling and cell adhesion. The brackets in red indicated the differentially methylated CpG sites that were consistent with
transcript level changes in pterygium.
doi:10.1371/journal.pone.0014687.g001
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drive EMT in many tumors [46]. In addition, MMP-2 is the
downstream gene of the b-catenin signaling pathway [47], and was
uniquely expressed in pterygium epithelial cells [1,32,33].
Pterygium formation has been reportedly linked to UV
radiation [1,48]. UV has also been known to trigger changes in
the action of methylating and demethylating enzymes [49,50]. We
therefore propose a mechanism whereby environmental influenc-
es, such as UV radiation can trigger tissue and temporal specific
changes in genes to initiate pterygium (illustrated in Figure 5).
Clinically, pterygium is primarily treated by surgical excision.
However, aggressive recurrences after surgery are fairly common
[51]. Profiling of methylation status of key matrix genes will not
only provide clues to pathogenesis but may also have prognosti-
cation value. Further studies are now required to establish this. In
addition, further work on the methylation status of the TGM-2,
MMP-2 and CD24 genes in other multi-factorial human non-
neoplastic diseases such as diseases involving scarring or aberrant
wound healing are warranted.
In conclusion, we have found aberrant DNA methylation to be
present in several key genes associated with wound healing
processes in pterygium. In our study, we found that critical CpG
islands associated with the MMP-2 and CD24 genes were
demethylated in pterygium, whereas TGM-2 gene sequences were
over-methylated. These results suggest that the pathogenesis of
pterygium may be related to the methylated state of pivotal wound
healing and developmental genes.
Materials and Methods
Ethics statement
The following protocols conformed to the tenets of the
Declaration of Helsinki and were approved by the institutional
Figure 3. Protein level and localization, as well as transcript level of transglutaminase 2 (TGM-2), matrix metalloproteinase 2 (MMP-
2), and CD24 in pterygium compared to conjunctiva. (A) Fold change of TGM-2, MMP-2, and CD24 gene transcript in the pterygium tissue
relative to the conjunctiva tissue. Height of the bars represents mean value and error bars represent standard error of the mean. Dashed line
represents the transcript levels of the conjunctiva. *p,0.05. (B) Immunofluorescent staining of TGM-2, MMP-2, and CD24. Nuclei were stained with
DAPI present in the mounting medium. Arrows indicate fibroblasts that were positive with MMP-2. Arrowheads indicate staining of CD24 in the
plasma membrane of epithelial cells. All images were taken at 400X magnification. (C) Western blot analysis of TGM-2, MMP-2, and CD24 proteins
expressed in human conjunctiva and pterygium tissue. GAPDH was used as the loading control. (D) In situ zymogram showing gelatinolytic activity in
the pterygium and conjunctiva tissue. Images were taken at 400X magnification.
doi:10.1371/journal.pone.0014687.g003
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written informed consent was acquired from all participating
patients.
Specimens from patients
The surgical excision and procurement of pterygium and
conjunctiva tissues from patients was carried out as previously
described [52]. Briefly, the pterygium tissue from a patient was
compared with the uninvolved conjunctival tissue obtained from
the same eye that was excised from the superior temporal
quadrant of the bulbar conjunctiva, adjacent to the position of the
harvested conjunctival graft.
Cell culture and treatment
IOBA-NHC were a gift from Yolanda Diebold at the University
of Valladolid, Spain. These cells were cultured in a medium
containing equal volumes of Dulbecco modified Eagle medium
(DMEM) and F12, with an additional 2 ng/ml recombinant
human EGF (R&D Systems, Minneapolis, MN), 1 mg/ml bovine
insulin, 0.1 mg/ml cholera toxin, 0.5 mg/ml hydrocortisone, and
10% FBS (all except EGF are from Invitrogen-GIBCO, Carlsbad,
CA). After reaching 80–90% confluency, the cells were treated
with 1, 2 or 3 mM of 5-aza-dC (Sigma, St. Louis, MO) for
24 hours. Some of the cells were left untreated.
Genomic region selection and DNA methylation analysis
The surgical samples were ground in liquid nitrogen with pestle
and mortar after fine chopping. Extraction and purification of DNA
from tissues was performed using the Genomic DNA Extraction Kit
(Norgen Biotek Corporation, Thorold, Canada). Quality control
was ascertained by ensuring that the ratio (260 nm:280 nm) of the
absorbanceofthe extractedDNAtobe1.80–1.95.Threesamples of
pterygium tissues and three un-involved conjunctiva tissues from 3
different patients were analysed in this study.
The EpiTYPER Sequenom Mass Array [53] service was
provided by Genetic Services, Sequenom, Inc. San Diego, CA.
For each sample, 1.25 mg of DNA in a volume of 25 mL was sent
to the service. Briefly, this is a previously validated, highly accurate
quantitative assay [54] based on base-specific cleavage and mass
spectrometry [55] after bisulfite treatment which converted all
non-methylated cytosine bases to uracil but with all methylated
cytosine bases remain cytosine [56]. This method of assaying for
DNA methylation status has been employed in lung cancer [57],
profiling of various cancer cell lines [58], developmental changes
[31], and differences in tissue function and differentiation [59].
Primers were designed for 48 sequences for 29 matrix and cell
adhesion related genes out of 36 genes, which were initially
selected for this study. Primers for the remaining 7 genes did not
yield satisfactory results and were excluded from the analysis.
Previously, we have performed a microarray analysis to
examine the transcript levels of .23000 genes using the
Affymetrix U133A Genechip [24], and the data have been made
available to the general public (GEO, http://www.ncbi.nlm.nih.
gov/gds/ with GEO series accession number GSE2513). The
methodology of this study has been reported elsewhere [24].
Genes with associated differential methylation of CpGs were
compared against the transcript changes detected on the gene
expression data from the Genechip. Upregulated transcripts were
considered to be consistent with hypomethylation and vice versa.
Subsequent analysis and results presented were focused on the
methylation changes that were consistent with differential gene
expression.
The sequences for some of the more significant sequences are
shown in Table 2. The median amplicon length was 389 bp (min
143, max 650). The median number of CpG units per amplicon
was 12 (min 3, max 44). Preliminary quality control (QC) steps
were applied to the data and the CpG units that yielded data in
greater than 25% of the samples passed initial QC. Data samples
Figure 4. Interacting pathways of transglutaminase 2 (TGM-2), matrix metalloproteinase 2 (MMP-2), and CD24 in pterygium.
Selected entities were analyzed with interacting TGM-2, MMP-2, and CD24 pathways by using Ariadne Pathway Studio 6.0.
doi:10.1371/journal.pone.0014687.g004
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amplicon were passed for that sample/amplicon pair. CpG units
which had data available for less than 25% of all samples were
excluded.
To visualize the proximity of the significant CpG islands from
the transcription and translation start sites, alignment of the
EpiTYPER target sequence with the appropriate NCBI nucleotide
sequence using ClustalW2 software (http://www.ebi.ac.uk/Tools/
clustalw2/index.html) was performed.
Real-time polymerase chain reaction
Primers shown in Table 3 were used for the detection of TGM-2,
MMP-2, and CD24 transcript. Reverse transcription of 1 mgo f
RNA for each sample was performed as previously described [60].
RT-PCR was performed by using the Lightcycler 480 System
(Roche Diagnostics, Basel, Switzerland). For this reaction, pre-
synthesized hydrolysis FAM (excitation wavelength of 483–533 nm)
probe was selected from the Universal ProbeLibrary set and used,
based on the ProbeFinder web-based assay (https://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000) de-
sign tool selecting for intron spanning assays. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as the internal
control. For each sample, triplicate wells were used. DCt was
calculated by subtracting the Ct of GAPDH from the Ct of the
targeted gene. The untreated IOBA-NHC cells and uninvolved
conjunctiva were considered as the calibrator to compare the
relative abundance of TGM-2, MMP-2, and CD24 gene transcript
in IOBA-NHC cells treated with 5-aza-dC and in pterygium tissue,
Figure 5. Pterygium pathogenesis. Environmental factors, such as UV exposure, have been known to trigger changes in DNA methylation. UV has
also been strongly associated with pterygium formation. This may suggest a mechanism whereby UV can trigger tissue and temporal specific
changes in matrix remodeling and cell adhesion related genes, such as transglutaminase 2 (TGM-2), matrix metalloproteinase 2 (MMP-2), and CD24 to
initiate pterygium formation. ERK1/2, FAK and VLA-4 are the abbreviations of extracellular signal-regulated kinase 1/2, focal adhesion kinase and very
late antigen-4, respectively.
doi:10.1371/journal.pone.0014687.g005
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2
(2DDCt), where DDCt=DCtsample2DCtcalibrator.
Immunofluorescent staining
Conjunctival tissues from normal conjunctival epithelium and
pterygium were sectioned with a Microm HM550 cryostat
(Microm, Walldorf, Germany) at 8 mm thickness. Sections were
fixed with 4% paraformaldehyde for 10 minutes, washed with 1X
PBS, and blocked with 4% BSA in 1X PBS containing 0.1%
Triton X-100 for one hour. Rabbit polyclonal antibodies against
TGM-2 (Abcam, Cambridge, UK) and MMP-2 (Abbiotec, San
Diego, CA), and mouse monoclonal antibody against CD24
(Neomarkers, Fremont, CA) were diluted with the blocking buffer
at a factor of 1:150, 1:200, and 1:100, respectively and incubated
at 4uC overnight. After washing with 1X PBS, the sections were
incubated with Alexa Fluor 488-conjugated secondary antibody
(Invitrogen) at room temperature for 1 hour. Slides were then
mounted with UltraCruz Mounting Medium containing DAPI
(Santa Cruz Biotechnology, Santa Cruz, CA). For negative
controls, non-immune serum was used in place of the specific
primary antibody. Sections were observed under and imaged with
a Zeiss Axioplan 2 fluorescence microscope (Zeiss, Oberkochen,
Germany).
In situ zymography
In situ zymography was performed to localize the gelatinase
activity in pterygium and conjunctiva cryosections using a previous
reported method [61]. Briefly, sections were incubated at room
temperature for 2 hours with reaction buffer (0.05 M TrisHCl,
0.15 M NaCl, 5 mM CaCl2, and 0.2 mM NaN3, pH 7.6)
containing 40 mg/ml FITC-labeled DQ gelatin, which was
available in a gelatinase/collagenase assay kit (EnzChek, Invitro-
gen). As a negative control, 50 mM 1,10-phenanthroline, a MMP
inhibitor, was added to the reaction buffer before applying the
FITC-conjugated DQ gelatin to frozen sections. Proteolysis of the
FITC-labeled DQ gelatin substrate yields cleaved gelatin-FITC
peptides that are fluorescent. The localization of fluorescence
indicates the sites of net gelatinolytic activity. After incubation, the
sections were washed three times with 1X PBS for 5 min,
counterstained with UltraCruz Mounting Medium containing
DAPI (Santa Cruz Biotechnology), and coverslip was applied.
Localization of gelatinolytic activity of MMPs was viewed and
imaged with a Zeiss Axioplan 2 fluorescence microscope (Zeiss).
Western blot
Normal conjunctiva and pterygium tissue were homogenized
individually into RIPA lysis buffer (Santa Cruz Biotechnology).
Insoluble materials were removed by 15-minute centrifugation,
10,000 g at 4uC. An equal volume of 4x SDS loading buffer was
added to each sample which was then subjected to boiling for
Table 2. Genomic regions analyzed for DNA methylation.
Gene promoter NCBI Accession Description Start* End*
CD24_01** NT_011875.12 Homo sapiens chromosome Y genomic contig, 7355993 7356344
GRCh37.p2 reference primary assembly.
Length=10102850
Features flanking this part of subject sequence:
Signal transducer CD24 precursor
CD24_02** As above As above 7356345 7355958
MMP-2 NT_010498.15 Homo sapiens chromosome 16 genomic contig, 9127643 9128045
GRCh37.p2 reference primary assembly.
Length=42003582
Features flanking this part of subject sequence:
72 kDa type IV collagenase isoform a preprotein
TGM-2 NT_011362.9 Bottom of Form Homo sapiens chromosome 20 genomic contig, 6989521 6989864
GRCh37.p2 reference primary assembly.
Length=31409461
Features flanking this part of subject sequence:
Protein-glutamine gamma-glutamyltransferase 2 isoform a
Protein-glutamine gamma-glutamyltransferase 2 isoform b
*Refers to position of target sequence in the sequence with the NCBI Accession mentioned.
**More than one EpiTYPER sequences were used for these promoters.
doi:10.1371/journal.pone.0014687.t002
Table 3. Primers used in real-time PCR.
NCBI
Gene Accession No. Primer Sequence
TGM-2 NM_004613.2 F: AGG GTG ACA AGA GCG AGAT G
R: TGG TCA TCC ACG ACT CCA C
MMP-2 NM_005430.4 F: ATA ACC TGG ATG CCG TCG T
R: AGG CAC CCT TGA AGA AGT AGC
CD24 NM_013230.2 F: CCA ACT AAT GCC ACC ACC A
R: GTG AGA CCA CGA AGA GAC TGG
GAPDH AF261085.1 F: AGC CAC ATC GCT GAG ACA
R: GCC CAA TAC GAC CAA ATC C
doi:10.1371/journal.pone.0014687.t003
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before reduction on a sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE-gradient 10%). The amounts of
protein applied was 40 mg. Resolved proteins were electrophoret-
ically transferred onto a nitrocellulose membrane and blocked in
1X TBS containing 5% non-fat milk, followed by overnight
incubation with the rabbit polyclonal antibodies against TGM-2
(Abcam; 1:500) and MMP-2 (Abbiotec; 1:1000), and mouse
monoclonal antibody against CD24 (Neomarkers; 1:500) in 4uC
with agitation. The membranes were then washed vigorously three
times each for five minutes in 1X TBS, 0.1% Tween-20. The
HRP-conjugated secondary antibodies (Santa Cruz Biotechnolo-
gy) were then applied at a dilution of 1:2000. Immunoreactivity
was visualized with Super Signal West Pico chemiluminescence
reagent (Pierce Biotechnology, Rockford, IL).
Statistical analysis
Student’s t-test or analysis of variance (ANOVA) followed by the
least significant difference (LSD) test were used to determine the
difference between groups. p,0.05 was accepted as significantly
different.
Supporting Information
Table S1 Entities that were analyzed in the pathways shown in
Figure 4
Found at: doi:10.1371/journal.pone.0014687.s001 (0.04 MB
DOC)
Table S2 Relationship between the entities analyzed in the
pathways shown in Figure 4
Found at: doi:10.1371/journal.pone.0014687.s002 (0.05 MB
DOC)
Figure S1 Hypermethylation of transglutaminase 2 (TGM-2)
promoter in the pterygium. The brackets indicate hypermethy-
lated CpG sites in pterygium (shown in Table 1). CGs highlighted
in grey represent CpG units that were not significantly methylated
or differentially methylated but not contributing to the dysregu-
lation of TGM-2 transcripts.
Found at: doi:10.1371/journal.pone.0014687.s003 (0.19 MB TIF)
Figure S2 Hypomethylation of matrix metalloproteinase 2
(MMP-2) promoter in the pterygium. The bracket indicates the
hypomethylated CpG site in pterygium (shown in Table 1). CGs
highlighted in grey represents the other CpG units that were tested
and found to be not significantly methylated.
Found at: doi:10.1371/journal.pone.0014687.s004 (0.34 MB TIF)
Figure S3 Hypomethylation of CD24 promoter in the pteryg-
ium. More than one EpiTYPER sequences were used for this
promoter: (A) CD24_01. (B) CD24_02. The brackets indicate the
differentially methylated CpG sites that were shown in Table 1.
CGs highlighted in grey show the other CpG units that were not
differentially methylated.
Found at: doi:10.1371/journal.pone.0014687.s005 (0.93 MB TIF)
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